Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial.

Lorcaserin is a serotonin 2c receptor agonist, which promotes weight loss while improving type 2 diabetes and atherogenic lipid profile without higher rates of major cardiovascular events. The full spectrum of the possible lorcaserin-induced cardiometabolic improvements remains to be clarified. Thus...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Diabetes Obes Metab
Huvudupphovsmän: Tuccinardi, Dario, Farr, Olivia M., Upadhyay, Jagriti, Oussaada, Sabrina M., Mathew, Hannah, Paschou, Stavroula A., Perakakis, Nikolaos, Koniaris, Anastasia, Kelesidis, Theodoros, Mantzoros, Christos S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6504613/
https://ncbi.nlm.nih.gov/pubmed/30724455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13655
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk